1.Cardiovascular Core Laboratories, MedStar Health Research Institute, Washington, United States
2. Houston Methodist Hospital, Houston, Texas, USA
3. University of Washington Medical Center, Seattle, USA
4. Baylor University Medical Center, Dallas, Texas, USA
5. Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, Minnesota, USA
6. Sanger Heart and Vascular Institute, Atrium Health, Charlotte, NC, USA
7. University Heart Center, University Hospital Zurich, Zurich, Switzerland
8. Los Robles Regional Medical Center, Thousand Oaks, California, USA
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention and external reviewers - has been published immediately upon acceptance as it was received in the last round of revision. The content of this article is the responsibility of the authors.
Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.
To read the full content of this article, please download the PDF.
Download full article (PDF)
Background: An independent panel of experts reviewed all investigator-reported cases of mitral valve leaflet adverse events (LAE) after MitraClipTM NTR/XTR in the EXPAND Study.
Aims: We aimed to report the findings of the expert panel and standardize definitions for LAE.
Methods: Standard definitions for different types of LAE were formulated and events adjudicated after detailed review by the expert panel.
Results: Enrolling centers reported LAE in 35 cases, 11 leaflet injuries (9 tear, 2 perforation) and 24 single leaflet device attachment (SLDA). The panel confirmed LAE in 20 cases (2.0% incidence), 18 patients had SLDA and 4 had leaflet injury (2 cases had both SLDA and injury). Leaflet injury occurred during device implant and resulted in surgical valve replacement or death. SLDA-alone events were identified during implant (n=2), pre-discharge (7) or at 30 days of follow-up (7) and were resolved (£ 2+ residual MR) with additional clips in 75% of cases.
Conclusions: Mitral valve repair with MitraClipTM NTR/XTR is safe. The rate of LAE is lower than previously reported using older generation devices. The proposed definitions and findings will help differentiate leaflet injury from inadequate leaflet insertion and SLDA, and provide guidance to consistently diagnose LAE post MitraClipTM.
mitral regurgitationmitral valve repairtransesophageal echocardiogrammiscellaneous
Interventions for valvular diseaseMitral valve replacement and repair
Read next article
Thirty-day outcomes of the Cardioband tricuspid system for patients with symptomatic functional tricuspid regurgitation: The TriBAND study